70 related articles for article (PubMed ID: 14722349)
1. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
[TBL] [Abstract][Full Text] [Related]
2. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
Speth F; Haas JP; Hinze CH
Pediatr Rheumatol Online J; 2016 Sep; 14(1):52. PubMed ID: 27623619
[TBL] [Abstract][Full Text] [Related]
3. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.
Yamasaki Y; Yamada H; Yamasaki M; Ohkubo M; Azuma K; Matsuoka S; Kurihara Y; Osada H; Satoh M; Ozaki S
Rheumatology (Oxford); 2007 Jan; 46(1):124-30. PubMed ID: 16754626
[TBL] [Abstract][Full Text] [Related]
4. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.
Papadopoulou C; Chew C; Wilkinson MGL; McCann L; Wedderburn LR
Nat Rev Rheumatol; 2023 Jun; 19(6):343-362. PubMed ID: 37188756
[TBL] [Abstract][Full Text] [Related]
5. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review.
Xia J; Jiang G; Jin T; Shen Q; Ma Y; Wang L; Qian L
BMC Pediatr; 2021 Nov; 21(1):488. PubMed ID: 34732158
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.
Rekeland IG; Fosså A; Lande A; Ktoridou-Valen I; Sørland K; Holsen M; Tronstad KJ; Risa K; Alme K; Viken MK; Lie BA; Dahl O; Mella O; Fluge Ø
Front Med (Lausanne); 2020; 7():162. PubMed ID: 32411717
[No Abstract] [Full Text] [Related]
7. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
Wu JQ; Lu MP; Reed AM
World J Pediatr; 2020 Feb; 16(1):31-43. PubMed ID: 31556011
[TBL] [Abstract][Full Text] [Related]
8. The Vasculopathy of Juvenile Dermatomyositis.
Papadopoulou C; McCann LJ
Front Pediatr; 2018; 6():284. PubMed ID: 30356795
[TBL] [Abstract][Full Text] [Related]
9. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.
Hinze CH; Oommen PT; Dressler F; Urban A; Weller-Heinemann F; Speth F; Lainka E; Brunner J; Fesq H; Foell D; Müller-Felber W; Neudorf U; Rietschel C; Schwarz T; Schara U; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):40. PubMed ID: 29940960
[TBL] [Abstract][Full Text] [Related]
10. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.
Hinze CH; Speth F; Oommen PT; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):38. PubMed ID: 29925381
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Deakin CT; Campanilho-Marques R; Simou S; Moraitis E; Wedderburn LR; Pullenayegum E; Pilkington CA;
Arthritis Rheumatol; 2018 May; 70(5):785-793. PubMed ID: 29342499
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Juvenile Dermatomyositis: An Update.
Papadopoulou C; Wedderburn LR
Paediatr Drugs; 2017 Oct; 19(5):423-434. PubMed ID: 28550457
[TBL] [Abstract][Full Text] [Related]
14. Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study.
Liang Y; Leng RX; Pan HF; Ye DQ
Med Sci Monit; 2017 May; 23():2543-2549. PubMed ID: 28548078
[TBL] [Abstract][Full Text] [Related]
15. Consensus-based recommendations for the management of juvenile dermatomyositis.
Bellutti Enders F; Bader-Meunier B; Baildam E; Constantin T; Dolezalova P; Feldman BM; Lahdenne P; Magnusson B; Nistala K; Ozen S; Pilkington C; Ravelli A; Russo R; Uziel Y; van Brussel M; van der Net J; Vastert S; Wedderburn LR; Wulffraat N; McCann LJ; van Royen-Kerkhof A
Ann Rheum Dis; 2017 Feb; 76(2):329-340. PubMed ID: 27515057
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.
Pagnini I; Vitale A; Selmi C; Cimaz R; Cantarini L
Clin Rev Allergy Immunol; 2017 Feb; 52(1):34-44. PubMed ID: 26429707
[TBL] [Abstract][Full Text] [Related]
17. Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.
De Paepe B; Zschüntzsch J
Int J Mol Sci; 2015 Aug; 16(8):18683-713. PubMed ID: 26270565
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review.
Ge Y; Peng Q; Zhang S; Zhou H; Lu X; Wang G
Clin Rheumatol; 2015 Jan; 34(1):99-105. PubMed ID: 25367345
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
